Morgan Stanley Summit Therapeutics Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 642,001 shares of SMMT stock, worth $12.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

642,001

Previous 478,126 34.27%

Holding current value

$12.1 Million

Previous $9.22 Million 48.12%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$16.64 - $36.7 $2.73 Million - $6.01 Million	163,875 Added 34.27%	642,001 $13.7 Million
Q1 2025 May 15, 2025	SELL	$16.65 - $23.76 $1.38 Million - $1.97 Million	-82,864 Reduced 14.77%	478,126 $9.22 Million
Q4 2024 Feb 14, 2025	SELL	$17.52 - $23.46 $285,716 - $382,585	-16,308 Reduced 2.82%	560,990 $10 Million
Q3 2024 May 14, 2025	BUY	$6.89 - $31.93 $1.65 Million - $7.67 Million	240,181 Added 71.25%	577,298 $12.6 Million
Q3 2024 Nov 14, 2024	BUY	$6.89 - $31.93 $1.65 Million - $7.67 Million	240,181 Added 71.25%	577,298 $12.6 Million
Q2 2024 May 14, 2025	SELL	$2.39 - $10.92 $535,056 - $2.44 Million	-223,873 Reduced 39.91%	337,117 $2.63 Million
Q2 2024 Oct 17, 2024	SELL	$2.39 - $10.92 $849,463 - $3.88 Million	-355,424 Reduced 51.32%	337,117 $2.63 Million
Q2 2024 Aug 14, 2024	SELL	$2.39 - $10.92 $849,463 - $3.88 Million	-355,424 Reduced 51.32%	337,117 $2.63 Million
Q1 2024 Oct 17, 2024	BUY	$2.55 - $5.07 $906,331 - $1.8 Million	355,424 Added 105.43%	692,541 $2.87 Million
Q1 2024 Aug 16, 2024	SELL	$2.55 - $5.07 $29,914 - $59,476	-11,731 Reduced 1.67%	692,541 $2.87 Million
Q1 2024 May 15, 2024	SELL	$2.55 - $5.07 $29,914 - $59,476	-11,731 Reduced 1.67%	692,541 $2.87 Million
Q4 2023 Aug 16, 2024	BUY	$1.67 - $2.83 $613,148 - $1.04 Million	367,155 Added 108.91%	704,272 $1.84 Million
Q4 2023 Feb 13, 2024	BUY	$1.67 - $2.83 $248,723 - $421,488	148,936 Added 26.82%	704,272 $1.84 Million
Q3 2023 Nov 15, 2023	SELL	$1.54 - $2.42 $56,441 - $88,693	-36,650 Reduced 6.19%	555,336 $1.04 Million
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.81 $234,676 - $499,575	-177,785 Reduced 23.1%	591,986 $1.49 Million
Q1 2023 May 15, 2023	BUY	$1.38 - $5.41 $760,150 - $2.98 Million	550,834 Added 251.59%	769,771 $1.35 Million
Q4 2022 Feb 14, 2023	SELL	$0.68 - $5.31 $90,032 - $703,044	-132,400 Reduced 37.68%	218,937 $930,000
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.63 $126,508 - $231,694	142,144 Added 67.95%	351,337 $418,000
Q2 2022 Oct 27, 2022	SELL	$0.92 - $2.38 $108,915 - $281,758	-118,386 Reduced 36.14%	209,193 $209,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.38 $108,915 - $281,758	-118,386 Reduced 36.14%	209,193 $209,000
Q1 2022 Oct 27, 2022	BUY	$2.0 - $3.45 $236,772 - $408,431	118,386 Added 56.59%	327,579 $803,000
Q1 2022 May 13, 2022	SELL	$2.0 - $3.45 $61,210 - $105,587	-30,605 Reduced 8.54%	327,579 $803,000
Q4 2021 Feb 14, 2022	BUY	$2.45 - $5.64 $196,583 - $452,542	80,238 Added 28.87%	358,184 $963,000
Q3 2021 Nov 15, 2021	BUY	$4.83 - $8.27 $1.34 Million - $2.3 Million	277,946 New	277,946 $1.39 Million

Others Institutions Holding SMMT

# of Institutions

266

Shares Held

90.9M

Call Options Held

4.71M

Put Options Held

3.17M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.8B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account